What is Flosonics Medical?
Flosonics Medical is dedicated to developing cutting-edge technology solutions aimed at enhancing clinical treatment delivery. The company's core innovation, the FloPatch, is the first wireless, wearable Doppler ultrasound system. This device is designed to streamline and inform clinical diagnoses, particularly in fluid resuscitation and management, leveraging the team's deep expertise in ultrasound technology, emergency, and critical care medicine. The FloPatch aims to provide clinicians with real-time diagnostic information, improving patient care and operational efficiency in critical settings.
How much funding has Flosonics Medical raised?
Flosonics Medical has raised a total of $44.2M across 4 funding rounds:
Other Financing Round
$5M
Unspecified
$14M
Series C
$20M
Unspecified
$5.2M
Other Financing Round (2018): $5M with participation from Toronto's iGan Partners
Unspecified (2021): $14M led by iGan Partners Inc, Genesys Capital, and Arboretum Ventures LLC
Series C (2024): $20M supported by Genesys Capital, iGan Partners, New Leaf Venture Partners, and Arboretum Ventures
Unspecified (2025): $5.2M featuring rbcX
Key Investors in Flosonics Medical
Genesys Capital
Genesys Capital is a Toronto-based venture capital firm focused on early-stage life sciences and healthcare companies, investing in biotechnology and medical innovation across North America.
iGan Partners
iGan Partners is one of Canada's largest healthcare-focused venture capital firms, investing across North America. The firm partners with exceptional founders to commercialize and scale innovative healthcare solutions.
Arboretum Ventures
Arboretum Ventures is a Midwest-based healthcare venture capital firm with over 20 years of experience in investing in innovative healthcare solutions, focusing on early-stage startups.
What's next for Flosonics Medical?
The substantial enterprise-level funding and recent strategic investment indicate Flosonics Medical is poised for significant scaling and market expansion. This capital infusion will likely fuel further research and development, enhance manufacturing capabilities, and broaden the company's commercial reach. The company's focus on innovative ultrasound technology for critical care positions it to capture a larger share of the medical device market, potentially leading to new product lines or deeper penetration into existing healthcare systems. The strategic backing suggests a clear path towards commercialization and widespread adoption of their unique diagnostic solutions.
See full Flosonics Medical company page
